|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||45.13 - 45.47|
|52 Week Range||39.06 - 47.89|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.07%|
One of the more notable themes in the world of exchange-traded funds last year was investors affinity for international equity funds. When 2017 drew to a close, five of the year's top 10 asset-gathering ...
Michael Hershey probably could have made a nice career out of selling real estate investments, but his clients needed more. “I started getting phone calls at night from clients, asking, ‘Can I afford this new car? Should I buy this sofa?’ ” says the JPMorgan advisor, who is Barron’s 21st-ranked advisor in Washington state.
The excitement surrounding the tournament and its impact on the stock world has led investors to look at ETFs that could act as a proxy for the game.
When Charles Brighton and his partner Jon Jones began talking up sustainable investing six years ago, they figured they’d mostly get uptake from their core clients—young, idealistic tech professionals around their Seattle offices. In just a few years, Brighton Jones has transitioned 10% of its $4.6 billion in assets to sustainable investing. “I can see a day coming, maybe a few years from now, when we say, ‘Let’s go all impact.’ ” Sustainable investing is growing fast as an investment category.
GlaxoSmithKline (GSK) estimates that almost 65% of the global multiple myeloma (or MM) drug sales are realized in the US. The demand in the MM segment is mainly driven by the aging population, which has resulted in rising annual incidence by around 2% for the disease. Currently, Johnson & Johnson’s (JNJ) anti-CD38 monoclonal antibody, Darzalex (daratumumb) is witnessing rapid uptake in the MM segment due to its higher efficacy as compared to the previous standard of care therapy.
On November 21, 2017, the U.S. Food and Drug Administration (or FDA) approved Jucala, a two-drug oral regimen comprising of dolutegravir and rilpivirine for patients suffering with HIV-1 infections who have not demonstrated treatment failure or history of drug resistance to the individual components of the new therapy. Juluca is commercialized by ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK), Pfizer (PFE), and Shinogi. Since the current standard of care includes three or more drugs, the two drug regimen could help reduce toxicity levels for treated patients.
GlaxoSmithKline (GSK) is a leading player in the global respiratory market with a major focus on the asthma and chronic obstructive pulmonary disease (or COPD) segments. The company has estimated global asthma prevalence to be around 250 million with 40% of the treated patients continuing to witness symptoms that affect the quality of their lives. To capitalize on this unmet demand, GlaxoSmithKline aims to deliver the right inhaled corticosteroid (or ICS) or combination regimen to the right patients and to ensure proper drug adherence.
2017 was another record year for assets flowing into exchange-traded funds (ETFs), and Vanguard was a big reason why. When it came to lost assets, not one Vanguard ETF was among last year’s worst offenders. By some estimates, Vanguard could be managing $10 trillion in total assets by 2023.
There is no denying investors' thirst for international exchange traded funds in 2017. As the U.S. bull market ages, investors are are flocking to low-fee ex-U.S. ETFs in search of new frontiers for potential ...
Wall Street analysts estimate that GlaxoSmithKline’s (GSK) top line could fall 0.8% to ~7.5 billion pounds in 4Q17.